Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golcadomide in Relapsed or Refractory T-cell Lymphomas in Japan
NCT06035497Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2023
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of golcadomide in T-cell lymphoma, sponsored by Bristol Myers Squibb. Primary endpoints: Adverse Events at 5 weeks, Treatment-Emergent Adverse Events at 5 weeks and 2 more. Started Nov 2023; status: active, not recruiting.
02
Drugs
golcadomide
03
Conditions
T-cell lymphoma
Beyond the preview
Go deeper on NCT06035497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06035497.